HAE
NYSEHaemonetics Corporation
$119.47
+17.76 (+17.46%)
2026-10-08 00:00
Healthcare
Medical Devices
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$4.64B
P/E Ratio
49.7
52W Low
52W High
$48.17
$121.00
Volume
2.8M
Analyst Rating
Hold
Target: $87
9 Analyst Ratings
Strong Buy
0
Buy
0
Hold
9
Sell
0
Price Target Range
Low: $80
Avg: $87
High: $106
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and s...
Employees
3,009
Website
haemonetics.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2026 | $1.33B | 18.1% | $97.3M | $326.0M |
| 2025 | $1.36B | 16.3% | $167.7M | $221.0M |
| 2024 | $1.31B | 12.6% | $117.6M | $219.9M |
| 2023 | $1.17B | 13.4% | $115.4M | $383.2M |
| 2022 | $993.2M | 8.1% | $43.4M | $268.8M |
| 2026 Q2 | $339.4M | 16.9% | $33.0M | $60.2M |
| 2026 Q1 | $346.4M | 14.9% | -$20.1M | $88.6M |
| 2025 Q4 | $339.0M | 20.5% | $44.7M | $99.9M |
| 2025 Q3 | $327.3M | 20.6% | $38.7M | $116.3M |
| 2025 Q2 | $321.4M | 16.8% | $34.0M | $21.1M |
| 2025 Q1 | $330.6M | 15.6% | $58.0M | $132.2M |
| 2024 Q4 | $348.5M | 16.9% | $37.5M | $52.3M |
| 2024 Q3 | $345.5M | 15.0% | $33.8M | $58.3M |